As part of its ongoing divestment program, a deal worth $2.1 billion has been struck between Johnson & Johnson (J&J) and US private equity firm Platinum Equity over the sale of the
Pharma giant Pfizer is injecting $600 million into its venture investment arm in a bid to ramp up its involvement in biotechnology and other emerging growth companies.
